Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
14.91
+0.44 (3.04%)
Real-time:   2:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.26 - 15.13
52 week 8.95 - 15.90
Open 14.52
Vol / Avg. 751,718.00/1.12M
Mkt cap 2.06B
P/E     -
Div/yield     -
EPS -1.90
Shares 119.47M
Beta 1.58
Inst. own 114%
Aug 4, 2014
Q2 2014 Ironwood Pharmaceuticals Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2014
Q2 2014 Ironwood Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 11, 2014
Ironwood Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 3, 2014
IRONWOOD PHARMACEUTICALS INC Annual Shareholder Meeting
May 13, 2014
IRONWOOD PHARMACEUTICALS INC at Bank of America Merrill Lynch Health Care Conference
Apr 29, 2014
Q1 2014 Ironwood Pharmaceuticals Inc Earnings Release
Apr 29, 2014
Q1 2014 Ironwood Pharmaceuticals Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -339.79% -1192.31%
Operating margin -303.92% -1101.36%
EBITD margin - -1050.10%
Return on average assets -57.05% -107.22%
Return on average equity -175.24% -299.34%
Employees 534 -
CDP Score - -

Address

301 BINNEY STREET
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Michael J. Higgins Chief Financial Officer, Chief Operating Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Gina Consylman Chief Accounting Officer, Vice President, Corporate Controller
Age: 42
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 75
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 72
Bio & Compensation  - Reuters
David A. Ebersman Independent Director
Age: 44
Bio & Compensation  - Reuters